Shanghai Yizhong Pharmaceutical (688091) Fundamentals 2026 — P/E 121.5x, Revenue Analysis | SniperIQ
Shanghai Yizhong Pharmaceutical (688091) is a CN-listed Healthcare company in Medical - Pharmaceuticals with a market capitalization of ¥8.2B, trading at ¥39.89 on the SHH. This SniperIQ fundamentals page covers Shanghai Yizhong Pharmaceutical's valuation (P/E 121.5x, P/B 5.6x), profitability (net margin 20.9%), revenue (¥317M in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Shanghai Yizhong Pharmaceutical's market cap?
Shanghai Yizhong Pharmaceutical (688091) has a market capitalization of approximately ¥8.2B, trading at ¥39.89 on the SHH. Market cap moves with the live share price.
What is Shanghai Yizhong Pharmaceutical's P/E ratio?
Shanghai Yizhong Pharmaceutical's trailing twelve-month P/E ratio is 121.5x, with a price-to-book (P/B) of 5.6x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Shanghai Yizhong Pharmaceutical?
Shanghai Yizhong Pharmaceutical runs a net profit margin of 20.9%, a gross margin of 100.5%, and an operating margin of 17.6%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Shanghai Yizhong Pharmaceutical generate?
Shanghai Yizhong Pharmaceutical reported revenue of ¥317M for fiscal year 2025, with net income of ¥65M and earnings per share (EPS) of 0.31. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Shanghai Yizhong Pharmaceutical pay a dividend?
Shanghai Yizhong Pharmaceutical does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is Shanghai Yizhong Pharmaceutical financially healthy?
Shanghai Yizhong Pharmaceutical carries a debt-to-equity ratio of 0.02x and a current ratio of 9.48x, with a market beta of -0.49. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Shanghai Yizhong Pharmaceutical a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Shanghai Yizhong Pharmaceutical (688091) the key facts are: market cap ¥8.2B, P/E 121.5x, revenue ¥317M, 52-week range 37.94-83.6. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Shanghai Yizhong Pharmaceutical's full fundamentals live
Get Shanghai Yizhong Pharmaceutical's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.